TGNA:FRA
Transgene SA
€0.67
arrow_downward
-0.15%(-0.00100) 1 天
10月15日, GMT+2 08:03:18 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 TGNA 生成关键数据洞见…
开盘价
€0.67
最高价
€0.67
最低价
€0.67
市值
1.92亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.48
52 周最低价
€0.60
每股收益
-€0.17
员工人数
152
开盘价
€0.67
最高价
€0.67
最低价
€0.67
市值
1.92亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.48
52 周最低价
€0.60
每股收益
-€0.17
员工人数
152
新闻报道
来自网络来源和新闻合作伙伴
CoinDesk
·
1天前
标普500期权成为该超流动交易所最热门的押注
Traders Union
·
1天前
Ryan Detrick：遵循中期选举年后的市场规律，S&P 500 自 2026 年 3 月 30 日以来上涨约 18%
亚洲日报
·
12小时前
纽约股市收盘：因物价冲击与半导体股疲软全面下跌，纳斯达克指数下跌1.88%
www.tmgm.com
·
1小时前
道琼斯期货在美国PPI和零售销售数据公布前上涨
资料
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Transgene SA简介